KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Current Assets (2017 - 2025)

Historic Current Assets for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Q3 2025 value amounting to $1.8 billion.

  • Amneal Pharmaceuticals' Current Assets rose 2148.85% to $1.8 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 billion, marking a year-over-year increase of 2148.85%. This contributed to the annual value of $1.6 billion for FY2024, which is 1523.69% up from last year.
  • Latest data reveals that Amneal Pharmaceuticals reported Current Assets of $1.8 billion as of Q3 2025, which was up 2148.85% from $1.6 billion recorded in Q2 2025.
  • Over the past 5 years, Amneal Pharmaceuticals' Current Assets peaked at $1.8 billion during Q3 2025, and registered a low of $1.3 billion during Q1 2023.
  • Moreover, its 5-year median value for Current Assets was $1.5 billion (2025), whereas its average is $1.5 billion.
  • As far as peak fluctuations go, Amneal Pharmaceuticals' Current Assets plummeted by 1206.74% in 2021, and later skyrocketed by 2148.85% in 2025.
  • Quarter analysis of 5 years shows Amneal Pharmaceuticals' Current Assets stood at $1.5 billion in 2021, then decreased by 7.12% to $1.4 billion in 2022, then fell by 2.41% to $1.4 billion in 2023, then increased by 15.24% to $1.6 billion in 2024, then rose by 15.79% to $1.8 billion in 2025.
  • Its last three reported values are $1.8 billion in Q3 2025, $1.6 billion for Q2 2025, and $1.5 billion during Q1 2025.